Aim: Growth Assessment Protocol is a fetal growth initiative designed to improve antenatal detection of babies who are small-for-gestational-age and reduce stillbirths. However, its direct impact on pregnancy outcome and stillbirth rates is questioned. This service evaluation aimed to assess Growth Assessment Protocol's influence on pregnancy outcomes at a National Health Service hospital.
Method: Anonymous, maternity and ultrasound data, routinely acquired between 2014 and 2022 were extracted from clinical databases (Viewpoint, Euroking). Trends in maternity data and ultrasound scan volume were explored with descriptive statistics. Variables of stillbirth, antenatal small-for-gestational-age detection and scan volume were compared before and after Growth Assessment Protocol implementation. Associations between these variables were evaluated using Spearman's rho.
Results: The percentage of babies born small-for-gestational-age reduced by 0.3% across the evaluation period. Antenatal small-for-gestational-age diagnosis rose from 4.1% to 14.3%. However, the number of false-positive cases of antenatally diagnosed small-for-gestational-age increased fivefold from 2.2% to 11.5%. Although stillbirth rates remained consistent post-Growth Assessment Protocol, complex scan volume (e.g. number of growth scans using Doppler) increased annually. The peak incline coincided with the Growth Assessment Protocol implementation period (2016-2018). Complex scan volume was significantly associated with overall small-for-gestational-age detection (rho = 0.8, =< 0.001), but not with stillbirth frequency (rho = -0.1, = 0.4).
Conclusion: Small-for-gestational-age detection increased following Growth Assessment Protocol implementation, although this was associated with a high false-positive rate and no reduction in stillbirths. The potential implications associated with clinical management, parent experiences and departmental workflow, alongside the benefits for stillbirth reduction, should be fully considered prior to the introduction of a new fetal growth initiative to the antenatal care pathway.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11563492 | PMC |
http://dx.doi.org/10.1177/1742271X241287925 | DOI Listing |
Curr Med Chem
January 2025
Department of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah, 21589, Saudi Arabia.
Background: Infertility was often considered a female issue, but male infertility emerged significantly after the Covid-19 pandemic. Hence, assessments are crucial for planning policies on health care and family planning and reasons thereof post vaccinations.
Material And Methods: The present study was a case-control, dual-centers, prospective study with normal sperm parameters.
Cureus
December 2024
Internal Medicine, University of Alexandria, Alexandria, EGY.
Aim: Thyroid nodules, based on high-resolution ultrasonography (HRUS), are among the most common endocrine abnormalities that affect the general population because of their high estimated prevalence rates. Fine needle aspiration cytology (FNAC) is a safe, cost-effective modality to differentiate between benign and malignant thyroid nodules based on the Bethesda System for Reporting Thyroid Cytopathology (BSRTC), thus avoiding unnecessary surgery. However, categories III and IV of BSRTC remain a controversial issue in clinical practice, encompassing a wide range of risks of malignancy.
View Article and Find Full Text PDFFront Plant Sci
January 2025
Institute of Crop Science, Huzhou Academy of Agriculture Sciences, Huzhou, China.
With the rapid advancement of plant phenotyping research, understanding plant genetic information and growth trends has become crucial. Measuring seedling length is a key criterion for assessing seed viability, but traditional ruler-based methods are time-consuming and labor-intensive. To address these limitations, we propose an efficient deep learning approach to enhance plant seedling phenotyping analysis.
View Article and Find Full Text PDFBMJ Oncol
October 2023
MRC Clinical Trials Unit at University College London, Institute of Clinical Trials and Methodology, London, UK.
Advances in the detection and treatment of cancer have translated into improved cancer survival rates and a growing population of cancer survivors. These include those living with cancer and individuals free of the disease following treatment. Epidemiological studies demonstrate that cancer survivors are at an increased risk of cardiovascular disease (CVD), with cardiovascular (CV) mortality overtaking cancer mortality in some tumour types.
View Article and Find Full Text PDFBMJ Oncol
December 2023
Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
Objectives: Non-mortality benefits of breast cancer screening are rarely considered in assessments of benefits versus harms. This study aims to estimate the rate of overdiagnosis in women with screen-detected breast cancer (SDBC) by allocating cases to either possibly overdiagnosed (POD) or not overdiagnosed categories and to compare treatment recommendations for surgery and adjuvant treatments by category, age at diagnosis and cancer stage.
Methods And Analysis: Retrospective secondary analysis of 10 191 women diagnosed with breast cancer in Australia and New Zealand in 2018.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!